The current state, opportunities and challenges for upscaling private investment in biodiversity in Europe.

European countries have committed to ambitious upscaling of privately funded nature conservation. We review the status and drivers of biodiversity finance in Europe. By implementing semistructured interviews with 25 biodiversity finance key informants and three focus groups across Europe, we explore opportunities and challenges for upscaling private investment in nature.

Climate change drives migratory range shift via individual plasticity in shearwaters.

How individual animals respond to climate change is key to whether populations will persist or go extinct. Yet, few studies investigate how changes in individual behavior underpin these population-level phenomena. Shifts in the distributions of migratory animals can occur through adaptation in migratory behaviors, but there is little understanding of how selection and plasticity contribute to population range shift.

Achieving biodiversity net gain by addressing governance gaps underpinning ecological compensation policies.

Biodiversity compensation policies have emerged around the world to address the ecological harms of infrastructure expansion, but historically compliance is weak. The Westminster government is introducing a requirement that new infrastructure developments in England demonstrate they achieve a biodiversity net gain (BNG). We sought to determine the magnitude of the effects of governance gaps and regulator capacity constraints on the policy's potential biodiversity impacts.

Compound heterozygous mutations further refine the critical promoter region for biotin-thiamine-responsive basal ganglia disease.

Mutations in the gene result in thiamine metabolism dysfunction syndrome 2, also known as biotin-thiamine-responsive basal ganglia disease (BTBGD). This neurometabolic disease typically presents in early childhood with progressive neurodegeneration, including confusion, seizures, and dysphagia, advancing to coma and death. Treatment is possible via supplement of biotin and/or thiamine, with early treatment resulting in significant lifelong improvements.

Successful treatment of refractory Trichomonas vaginalis infection using intravenous metronidazole.

Trichomonas vaginalis is a sexually transmitted protozoan infection resulting in a vulvo-vaginitis and altered vaginal discharge in symptomatic women. Since its introduction in the 1960 s, metronidazole has been the first-line drug for trichomonal infection. Other nitroimidazoles, such as tinidazole, are used as alternative regimens with similar activity but at a greater expense.